Dr. Doyle brings more than 20 years of clinical development experience in industry and academia to Aro’s leadership team
Philadelphia, PA, October 7, 2021 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the appointment of Mittie Doyle, MD, FACR as Chief Medical Officer and a member of the company’s executive leadership team.
Dr. Doyle is a proven research physician who has held numerous leadership roles in clinical development. She joins Aro with over 20 years of experience in the pharmaceutical/biotech industry and academia, and most recently served as Vice President, Global Therapeutic Area Head, Research & Development, Immunology at CSL Behring. Prior to her time at CSL, Dr. Doyle held senior level roles at Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals; during her career, she has led clinical development across a broad range of immune mediated and orphan diseases. She has led teams with responsibilities for design and execution of first-in-human through phase 2 and 3 trials, resulting in several global regulatory approvals. Dr. Doyle received her BA magna cum laude from Princeton University in Romance Languages and her MD cum laude from Yale Medical School. She completed her postdoctoral training at Harvard Medical School including residency in Internal Medicine at Massachusetts General Hospital and clinical/research fellowship in Rheumatology and Immunology at Brigham and Women’s Hospital.
“Mittie’s addition to our executive leadership team adds deep clinical development expertise as we move closer to advancing our lead Centyrin pipeline programs into the clinic”, said Susan Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics. “Her experience across multiple therapeutic areas, including autoimmune and genetic diseases, will be an important asset in helping Aro fulfill the broad potential of our Centyrin platform.”
About Aro Biotherapeutics
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit www.arobiotx.com.
Source: Aro Biotherapeutics